Prurigo Nodularis: An Older African American Female Adult Presenting With Nodular Lesions and Persistent Itching

Target Audience

The target audience will be comprised of dermatologists, specialty nurse practitioners, specialty physician assistants, and managed care pharmacists.

Program Overview

Prurigo nodularis (PN) is a chronic condition mediated by immune and neural dysregulation and presenting with highly pruritic, hyperkeratotic papules or nodules; the condition disproportionately affects African American patients compared to the general population. There are currently no FDA-approved therapies for the treatment of PN, leading to a high level of variability in clinical practice and the use of off-label agents; the current treatment landscape, or lack thereof, highlights the need for a multimodal approach to therapy and consideration of emerging agents. As a result, many health care professionals may be unaware of the standard, off-label treatments used, as well as the clinical data surrounding promising emerging agents for PN management and as a result, may miss opportunities to deliver evidence-based care. Join our expert faculty as they discuss patient scenarios utilizing methods to avoid missed opportunities for the care team, assess the clinical efficacy and safety of standard off-label, as well as emerging therapies, and ultimately devise effective treatment plans that encourage long-term adherence and address residual disease burden for patients with PN.

Learning Objectives

Upon completion of this educational activity, learners should be better able to:

ANALYZE clinical data surrounding emerging treatments for PN
ASSESS the efficacy of standard, off-label treatments currently used for PN and residual burden of disease on patients
DEVELOP evaluation criteria for prurigo nodularis (PN) that incorporates characteristic features, including symptoms, presentation, and comorbidities
DEVISE a treatment plan that encourages long-term adherence